Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
View Patent ↗The present invention relates to bicyclic nucleosides and oligomeric compounds comprising at least one such nucleoside. These oligomeric compounds typically have enhanced binding affinity and nuclease resistance properties compared to unmodified oligomeric compounds. The oligomeric compounds are useful, for example, for investigative and therapeutic purposes.
1. A method of reducing target messenger RNA levels in an animal comprising administering to said animal an oligomeric compound comprising a sequence of linked nucleosides and nucleoside analogs which is 100% complementary to said target messenger RNA and has the structure:
T 1 -(Nu 1 -L 1 ) n1 -(Nu 2 -L 2 ) n2 -(L 3 -NU 3 ) n3 -T 2
wherein:
each Nu 1 and Nu 3 is, independently, a high affinity modified nucleoside,wherein at least one of Nu 1 and Nu 3 is a bicyclic nucleoside analog;
each Nu 2 is a 2′-deoxy nucleoside;
each L 1 , L 2 is a phosporothioate internucleoside linking group;
each L 3 is a phosphorothioate internucleoside linking group except that one of L 3 is a single bond when attached to L 2 1
each T 1 and T 2 is, independently, H or an optionally linked conjugate group;
n1 is from 1 to about 3;
n2 is from 12 to about 16; and
n3 is from 1 to about 3
wherein the total of n1, n2 and n3 is 14 to 21.
2. The method of claim 1 wherein each of the high affinity modified nucleosides is, independently, a bicyclic nucleoside analog, a 2′—O—(CH 2 ) 2 —O—CH 3 modified nucleoside, a 2′-F modified nucleoside, or a 2′—O—CH 2 —C(═O)—NR 1 R 2 modified nucleoside;
each R 1 and R 2 is, independently, H, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, or substituted or unsubstituted C 2 -C 10 alkynyl; and
each substituted group is mono or poly substituted with OR 1 , SR 1 , NH 3 + , NR 1 R 2 , guanidino or acyl, wherein the acyl is an acid amide or an ester.
3. The method of claim 2 wherein the at least one bicyclic nucleoside analog has a 4′—CH 2 —O—2′ bridge or a 4′—(CH 2 ) 2 —O—2′ bridge.
4. The method of claim 2 wherein each R 1 and R 2 is, independently, H or C 1 -C 10 alkyl.
5. The method of claim 1 wherein at least one Nu 1 nucleoside and at least one Nu 3 nucleoside is a bicyclic nucleoside analog comprising a 4′—CH 2 —O—2′ bridge or a 4′—(CH 2 ) 2 —O—2′ bridge.
6. The method of claim 1 wherein at least one of the 5′-most or 3′-most terminal affinity modified nucleosides is a bicyclic sugar modified nucleoside comprising a 4′—CH 2 —O—2′ bridge or a 4′—(CH 2 ) 2 —O—2′ bridge.
7. The method of claim 1 , wherein n2 is 12.
8. The method of claim 1 , wherein n2 is 14.
9. The method of claim 1 , wherein n2 is 16.
10. The method of claim 1 , wherein n1 and n3 are 4.
11. The method of claim 1 , wherein n1 and n3 are 3.
12. The method of claim 1 , wherein n1 and n3 are 2. 13
13. The method of claim 1 , wherein n1 and n3 are 1.
14. The method of claim 1 , wherein the total of n1, n2 and n3 is 14 to 18.